BIOCRYST PHARMACEUTICALS INCBCRXEarnings & Financial Report

Nasdaq · pharmaceutical industry

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

NextMar 31, 2026

Revenue

$159.4M

Gross Profit

$157.2M

Operating Profit

$29.6M

Net Profit

$12.9M

Gross Margin

98.6%

Operating Margin

18.6%

Net Margin

8.1%

YoY Growth

36.1%

EPS

$0.06

Financial Flow

BIOCRYST PHARMACEUTICALS INC Q3 2025 Financial Summary

BIOCRYST PHARMACEUTICALS INC reported revenue of $159.4M for Q3 2025, with a net profit of $12.9M (8.1% margin). Cost of goods sold was $2.2M, operating expenses totaled $127.6M.

Key Financial Metrics

Total Revenue	$159.4M
Net Profit	$12.9M
Gross Margin	98.6%
Operating Margin	18.6%
Report Period	Q3 2025

BIOCRYST PHARMACEUTICALS INC Annual Revenue by Year

BIOCRYST PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $450.7M).

Year	Annual Revenue
2024	$450.7M
2023	$331.4M
2022	$270.8M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$93.4M	$92.8M	$109.3M	$117.1M	$131.5M	$145.5M	$163.4M	$159.4M
YoY Growth	17.4%	34.9%	32.5%	35.0%	40.8%	56.9%	49.4%	36.1%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$517.0M	$467.9M	$472.4M	$491.3M	$490.4M	$480.0M	$457.2M	$446.4M
Liabilities	$972.5M	N/A	N/A	$959.8M	$966.4M	$932.0M	$878.8M	$834.3M
Equity	$-455.5M	$-476.2M	$-475.6M	$-468.6M	$-475.9M	$-451.9M	$-421.6M	$-387.9M